PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., June 02, 2022 — PDS Biotechnology … Continue reading PDS Biotechnology (NASDAQ: PDSB) Granted FDA Fast Track Designation for Lead Candidate PDS0101